Male germ cell-associated kinase (MAK), a direct transcriptional target of androgen receptor (AR), is a co-activator of AR. In this study, we determined the activating mechanism of MAK and identified a previously unknown AR-independent role of MAK in mitosis. We found that MAK kinase activity requires dual phosphorylation of the conserved TDY motif and that the phosphorylation is dynamic during cell cycle. MAK associates with CDH1 (FZR1, fizzy/cell division cycle 20 related 1) and phosphorylates CDH1 at sites phosphorylated by cyclin-dependent kinases. When MAK is overexpressed, the binding of CDH1 to anaphase promoting complex/cyclosome decreased, resulting in an attenuation of anaphase-promoting complex/C ubiquitin ligase activity and the consequential stabilization of the CDH1 targets such as Aurora kinase A and Polo-like kinase 1. As such, overexpression of MAK leads to mitotic defects such as centrosome amplification and lagging chromosomes. Our immunohistochemistry result showed that MAK is overexpressed in prostate tumor tissues, suggesting a role of MAK in prostate carcinogenesis. Taken with our previous results, our data implicate MAK in both AR activation and chromosomal instability, acting in both early and late prostate cancer development.
Introduction
For more than a decade in the United States, prostate cancer has been the most frequently diagnosed cancer in men and among the top three leading causes of cancerrelated deaths. As a hormonally regulated malignancy, prostate cancer goes through different phases of hormone dependence. At early stage, growth and survival of the cancer cells rely heavily on androgen signaling and androgen receptor (AR). At a later stage, especially upon hormone deprivation therapy, a significant portion of prostate cancers transition into an androgen-independent or castration-resistant state, where the requirement for androgen is less (Feldman and Feldman, 2001; Gregory et al., 2001; Chen et al., 2004) . Some castration-resistant cells derived from metastasis even lose androgen dependency altogether with no AR expression (Mendiratta et al., 2009) . Multiple mechanisms have been ascribed to account for the disease progression to castration-resistant and metastatic state. One mechanism that has received less attention is chromosomal instability (CIN), although translocation, copy-number changes and gain/loss of oncogenes/tumor suppressor genes were frequently reported (Shand and Gelmann, 2006; Clark and Cooper, 2009) . Mitotic defects associated with chromosomal aberrations are often observed in prostate cancer cell lines and patient tissues, and the degree of abnormalities positively correlates with tumor staging (Tribukait, 1991; Beheshti et al., 2001; Pihan et al., 2001) .
Overexpression or mutations of proteins such as PIM-1, Aurora kinase A, Polo-like kinase 1 (PLK1) and Id1 are found in prostate cancer cells, causing defect in mitotic checkpoint, deregulation of anaphase-promoting complex/cyclosome (APC/C) or centrosome amplification, which further lead to CIN and aneuploidy (Roh et al., 2003; Weichert et al., 2004; Buschhorn et al., 2005; Wang et al., 2008) . The E3 ubiquitin ligase complex APC/C and CDH1 (or FZR1, fizzy/cell division cycle 20 related 1) has a crucial role in maintaining proper levels of mitotic proteins and regulating the timely progression of cell cycle. In fact, deregulation of APC/C CDH1 complex (APC/C CDH1 ) is frequently seen in cancers with mitotic defects and CIN.
Male germ cell-associated kinase (MAK) belongs to a protein kinase family characterized by a catalytic domain resembling a hybrid of the TXY motif found in mitogen-activated protein kinases and the TY motif in cyclin-dependent kinases (CDK) (Payne et al., 1991; Brown et al., 1999; Xia et al., 2002; Fu et al., 2005) . Despite the hybrid signature, virtually nothing is known about the post-translational kinase-activating mechanism for MAK. We previously reported that MAK was transcriptionally activated by androgen (Xia et al., 2002) and a high level of MAK transcript was found in several prostate cancer cell lines (Robinson et al., 1996; Ma et al., 2006) . MAK, in turn, functions as a critical AR co-activator and is required for androgen-dependent cell proliferation (Ma et al., 2006) . These findings suggest that MAK may contribute to prostate carcinogenesis through AR signaling. However, our observation of MAK also being highly expressed in AR negative, castration-resistant cell lines (DU145 and PC3) (Xia et al., 2002) suggests additional, AR-independent roles of MAK in prostate carcinogenesis.
Human MAK shares high degrees of homology to rat (90%) and mouse (89%) orthologues (Xia et al., 2002) , whose expression are exclusively enriched in testicular germ cells during meiosis (Matsushime et al., 1990; Koji et al., 1992) . It is thus likely that human MAK is involved in meiosis and/or cell cycle control, potentially contributing to prostate cancer progression in an ARindependent manner.
In this study, we report that MAK is overexpressed in prostate cancer cell lines and clinical specimens. We demonstrate that dual phosphorylation of the conserved TDY is required for MAK kinase activation, and that this phosphorylation displays a dynamic pattern during cell cycle. In addition, a novel function of MAK acting as a negative regulatory kinase of APC/C CDH1 is described. A new role of MAK in the context of prostate carcinogenesis will be discussed.
Results

MAK is overexpressed in prostate cancer cells
We previously reported that compared with PrEC normal prostate epithelial cell, MAK transcripts are elevated in several cancer cell lines (Xia et al., 2002) . In this study, we generated a highly specific antibody (Supplementary Figure S1) Figure S2) , high levels of MAK protein were detected in the castration-resistant cancer cell lines CWR22Rv1, DU145 and PC3 (Figure 1a) . We also found that it was localized in the nuclear fraction of the cell lysates (Figure 1b) . Interestingly, MAK protein is barely detectable in androgen-sensitive LNCaP cell, even though the transcript level was shown to be increased by androgen (Figure 1a ) (Xia et al., 2002) . As MAK is an androgen-regulated gene, it was surprising that the AR-negative PC3 and DU145 cells overexpress MAK, suggesting an AR-independent mechanism regulating MAK expression during prostate carcinogenesis.
To study MAK expression in prostate cancer specimens, a human microarray containing prostate tissues from 15 normal, 25 hyperplasia and 26 malignant individuals was stained for MAK with our antibody (Figure 1c) . The MAK expression level in each tissue core was quantified using (1) manual scoring by expert pathologists on a scale from 0 to 3, 3 indicating the highest intensity (Figure 1d MAK is activated via phosphorylation of the TDY motif Earlier studies on MRK (MAK-related kinase/ ICK; another member of the MAK kinase family) revealed that the dual phosphorylation on the TDY motif, was carried out by its autokinase activity and by CCRK (human cell cycle-related kinase) (Fu et al., 2005 (Fu et al., , 2006 . This dual phosphorylation is required for MRK's full kinase activity. We therefore tested the possibility of MAK being activated in a similar manner. The conserved T157 and Y159 (of TDY) were substituted with alanine and phenylalanine, respectively, to yield the following mutants: ADY, TDF and ADF. Wild-type (wt) MAK strongly phosphorylated myelin basic proteins in vitro (Figure 3b upper), and exhibited autophosphorylation on the TDY motif in vivo as detected by the antibody that specifically recognizes the dual-phosphorylated TXY (Figure 3b lower) . When the TDY motif is mutated, however, the phosphorylation activity on myelin basic protein was diminished to similar level of MAK (KR), an inactive mutant carrying arginine substitution for the conserved lysine in the ATP-binding pocket ( Figure 3b ). We conclude that dual phosphorylation on the TDY motif is crucial for MAK activity, and that the autokinase activity is required for this phosphorylation. This dual phosphorylation of MAK in vivo was enhanced by overexpression of CCRK (Figure 3c ), which also physically interacted with MAK ( Figure 3d ). MKKs that are known to phosphorylate the TEY motif of mitogen-activated protein kinases, however, did not enhance MAK phosphorylation (data not shown). Taken together, MAK is specifically phosphorylated on the conserved TDY motif by CCRK and by autokinase activity; such phosphorylation status is indicative of its kinase activity.
Given its dynamic subcellular localization (Figure 2 ), we next determined whether the expression or activity of MAK is regulated along cell cycle. The endogenous MAK expression in DU145 and PC3 cells appeared to be generally constant at different stages (data not shown), whereas the TDY-dual phosphorylation, an index of its kinase activity, oscillated during cell cycle ( Figure 3e ). HEK293 cells stably expressing MAK-V5H protein were synchronized at different cell cycle stages to examine the extent of MAK phosphorylation: it increased from S, peaked at G2 to early M phase and decreased at late M phase ( Figure 3e ). The high level phosphorylation of MAK during G2/M suggests a role before the onset of anaphase, possibly during the metaphase-anaphase transition.
MAK binds to and phosphorylates CDH1
The transition between metaphase to anaphase is mediated by APC/C, whose E3 ubiquitin ligase is activated sequentially by binding to two activators: CDC20 and CDH1/FZR1. Activation of APC/C consequently triggers proteolysis of several mitotic proteins from anaphase to G1. A study in budding yeast reported that the MAK homolog Ime2 negatively regulates APC/ C through CDH1 during meiosis (Bolte et al., 2002) . To explore the role of MAK during cell cycle, we tested whether MAK is involved in the regulation of APC/C. As demonstrated by immunoprecipitation of ectopically expressed ( Figure 4a ) or endogenous ( Figure 4b ) MAK, CDH1 was found to associate to MAK, whereas no association between MAK and CDC20 was detected (data not shown). A reciprocal experiment of CDH1 immuoprecipitaion confirmed the MAK-CDH1 interaction (Supplementary Figure S3A) . The interaction domain was mapped to the WD40 domain of CDH1 (Supplementary Figure S3B) , a region involved in substrate binding and the subsequent ubiquitination mediated by APC/C CDH1 (Kraft et al., 2005) . Overexpression of CDH1 leads to CDH1-mediated substrate We next determined whether MAK regulates CDH1 by phosphorylation. In vitro kinase assays showed that CDH1 is indeed phosphorylated by wt MAK, either immunoprecipitated from mammalian ( Figure 5a ) or purified from bacteria cells (Figure 5b ). The MAK KR and ADF mutants, however, exhibited very limited phosphorylation activity toward CDH1. As the phosphorylation of MAK, an index of kinase activity, increased from G2 to early mitosis (Figure 3e ), we tested whether MAK-mediated phosphorylation of CDH1 also displays a similar pattern during cell cycle. This turned out to be the case, based on phosphoryla- HEK293 cells stably expressing MAK-V5H were synchronized at G1/S transition by double-thymidine block and released in complete medium at time 0. After release, cells were harvested at the indicated time points, and the cell lysates were analyzed by western blotting. Phosphorylation and total level of MAK was detected by anti-phospho-MAPK and anti-V5 antibodies, respectively. Cyclin-B1 and phospho-histone H3Ser10 indicate the progression of cell cycle.
tion of CDH1 by MAK IP from HEK293 cells (Figure 5b ). To exclude the possibility that CDK is non-specifically bound in the MAK immunoprecipitated complex, contributing to the in vitro CDH1 phosphorylation, we blotted the IP samples for CDK1 and CDK2, and could not detect either (Supplementary Figure S4) . These results suggest a cell cycle-dependent phosphorylation of CDH1 by MAK. Before entering and until the end of mitosis, the activity of APC/C CDH1 is mainly negatively regulated by CDK-dependent phosphorylation of CDH1 (Zachariae et al., 1998; Jaspersen et al., 1999; Lukas et al., 1999; Kramer et al., 2000) . We developed two CDH1 mutants with alanine substitutions at the known CDK phosphorylation sites to determine whether MAK phosphorylates CDH1 on similar residues. Mutant CDH1(4A) lacks the four major phosphoacceptor sites of CDK (S40A, T121A, S151A, S163A) and mutant CDH1(9A) lacks all nine acceptor sites (T32, S36, S40, S70, T121, S138, S146, S151, S163) (Zachariae et al., 1998; Jaspersen et al., 1999; Kramer et al., 2000) . Phosphorylation of CDH1(4A) by Escherichia coli-purified MAK was significantly diminished, and only marginal phosphorylation of CDH1(9A) could be detected (Figure 5c ). In addition to the bacterially expressed kinase, MAK isolated from mammalian cells also exhibited the same phosphorylation specificity toward CDK sites; only background level of phosphorylation of CDH1(9A) by the immunoprecipitated MAK could be detected (Figure 5b) . Thus, MAK phosphorylates CDH1 during G2 to M phase on multiple sites overlapping with those by CDK.
Overexpression of MAK inhibits APC/C CDH1 activity Upon CDK-mediated phosphorylation, CDH1 dissociates from CDC27, a subunit of APC/C, resulting in the inactivation of APC/C ubiquitin ligase and the consequent target stabilization (Kraft et al., 2005) . Phosphorylation of CDH1 by MAK on the CDK sites suggest a similar role of MAK as CDK. Indeed, when MAK was overexpressed, the association between CDH1 and CDC27 reduced significantly (Figures 6a and b) , indicating that the CDH1-dependent activation of APC/C was inhibited. The APC/C E3 ligase activity was accordingly reduced, as reflected by the significantly decreased level of ubiquitinated Aurora A in MAKoverexpressing cell (Figure 6c ). The ubiquitination of Aurora A in MAK (KR)-overexpressing cells was reduced to a lesser extent (Figure 6c ). The inhibition of APC/C CDH1 thus results in increased level ( Figure 6d ) and stability (Figure 6e ) of the target proteins Aurora kinase A and PLK1. Together, our results suggest that overexpression of MAK inhibits APC/C CDH1 activity in vivo, principally by a phosphorylation-dependent mechanism (Figure 8a ).
Overexpression of MAK results in extra centrosomes and lagging chromosome As described above, MAK is overexpressed in prostate cancer cells. This, together with the result that MAK affects APC/C activity and aberrantly stabilizes Aurora kinase A and PLK1, prompted us to further examine whether mitosis in prostate cancer cells is mis-regulated by MAK overexpression. With limited endogenous MAK expression (Figure 1a ) and an intact p53/Rb pathway, LNCaP was a suitable cell line to study the role of MAK overexpression in mitosis. We generated a LNCaP cell line ectopically overexpressing MAK-V5H (LNCaP/MAK-V5H). Similar to what we observed in HEK293 and 293T cells, LNCaP/MAK-V5H cells showed stabilization of Aurora kinase A and PLK1 (Figure 7a ), suggesting that MAK-mediated inhibition of APC/C CDH1 is not cell type specific. The mis-regulated APC/C CDH1 activity did not seem to affect cell cycle progression as no apparent change of overall cell proliferation rate and cell cycle distribution was observed in LNCaP/MAK-V5H cells, whether cultured in the presence or absence of androgen (data not shown).
Since it is well recognized that tight regulation of APC/C is critical for mitosis and genomic stability, the potential mitotic defects caused by MAK overexpression was examined. vec (Figure 7c) , indicating an increased rate of chromosome mis-segregation and chromosomal instability. In light of these findings, we suggest that in addition to the activation of AR, MAK has a role in chromosomal stability in prostate cancer cells (Figure 8b ), affecting both early and late phase of carcinogenesis.
Discussion
In this study, we developed a highly specific MAK antibody, and confirmed that the expression levels of MAK are elevated in castration-resistant prostate cancer cell lines. In agreement with the cell line results, immunohistochemistry analysis shows that MAK is generally overexpressed in prostate tumor tissues. To our surprise, however, MAK protein level is much lower in the androgen-sensitive LNCaP cell. Despite the low level, it is essential for LNCaP cell growth, as small interfering RNA knockdown of MAK significantly reduced AR response and resulted in growth inhibition (Ma et al., 2006) . Immunostaining of endogenous MAK protein in DU145 and PC3 cells reveals a dynamic subcellular localization during cell cycle: it is localized to the mitotic spindle and centrosomes In vitro phosphorylation of CDH1 by MAK. GST and GST-CDH1 fusion proteins used in this assay were expressed and purified from E. Coli. (a) Phosphorylation of GST-CDH1 by MAK immunoprecipitated from 293T cells using V5 antibody. 32 P-ATP was specifically incorporated to CDH1 but not GST. (b) Cell cycle-dependent CDH1 phosphorylation by MAK. HEK293 cells expressing MAK-V5H were arrested at G1/S (time 0) for synchronization. Cells at indicated time points after releasing were harvested for MAK IP, followed by in vitro kinase assay (IVK) using GST-CDH1 (wt or 9A) as substrate. Western blot (WB) of immunoprecipitated MAK shows equal amount of MAK used for each IVK reaction. Cyclin B1 expression serve as a marker for different phases of cell cycle. Intensity of the phosphorylated CDH1 (wt) was quantified by Quantity One (BioRad Lab Inc., Hercules, CA, USA). The value of each time point, after subtracting background signal, was divided by that of time 0, and the folds increase during cell cycle is shown in the bargraph. (c) Phosphorylation of CDH1 by E. coli expressed and purified GST-MAK. Purified wt, KR or ADF MAK was reacted with CDH1 protein wt, 4A or 9A to determine the phosphorylation specificity. Arrowheads indicate 32 Plabeled proteins, coomassie staining shows equal protein loaded. Experimental repeats n ¼ 2.
MAK inhibits APC/C
CDH1 in prostate cancer cell L-Y Wang and H-J Kung during metaphase and anaphase, and to the mitotic midbody from anaphase to telophase. Together, we speculate that although limited expression of MAK in LNCaP cell is sufficient to maintain survival and cell growth through AR signaling, overexpression of MAK associated with castration-resistant cancer cells may contribute to malignancy via aberrant regulation of mitosis ( Figure 8 ). This is the first study on the post-translational regulation of MAK activity. Our results showed that, similar to human MRK and yeast Ime2, dual phosphorylation of the conserved TDY motif is required for MAK to acquire full kinase activity. The dual phosphorylation of MAK is mediated by autophosphorylation and partially by CCRK, which coincident with MAK, is enriched in testis (Wohlbold et al., 2006) . Interestingly, we found that this phosphorylation indicative of MAK activity, oscillates during cell cycle. The phosphorylation of MAK increases between S and G2, reaches maximum at early mitosis and drastically decreases at the end of mitosis.
We further provide evidence showing that MAK negatively regulates APC/C CDH1 through a phosphorylation scheme similar to CDK-dependent inactivation of CDH1. First, MAK physically interacts with CDH1, and colocalizes with CDH1 in the nucleus during G1 and at the centrosomes during mitosis (Zhou et al., 2003) . Second, bacterial-and mammalian-expressed MAK both show phosphorylation specificity toward CDH1 on a number of CDK-phosphorylation sites in vitro. Third, MAK mediates CDH1 phosphorylation with increasing levels from G2 to M phase, coincident CDH1 on Aurora A. Flag vector or Flag-Aurora A was co-expressed with V5H vector, MAK-V5H wt or KR, as well as HA-Ubiquitin in 293T cells. The specific ubiquitination of Aurora A was detected in the Flag-immunoprecipitants by western blotting with anti-HA. (d) Higher protein level of Aurora A and PLK1 in MAK-overexpressing cell. The protein levels in 293T cells expressing V5H vector or MAK-V5H were analyzed by western blot with specific antibodies. (e) HEK293 cells stably expressing V5H vector or MAK-V5H were treated with 100 nM nocodazole for G2/M-phased cell enrichment, followed by cyclohexamide treatment for the indicated time points. The protein levels were quantified by AlphaView SA (Cell Biosciences, Inc, Santa Clara, CA, USA), and the quantified values were normalized against bactin values. Compared with cyclohexamide-untreated sample (time 0), the relative levels of Aurora A and PLK1 at each time points were indicated by percentage. Same result was observed in at least three independent experiments. (n43) with the APC/C CDH1 inactivation pattern. Forth, overexpression of MAK results in the following related events: (a) the dissociation of CDH1 and APC/C via subunit CDC27, (b) the attenuation of APC/C CDH1 activity on ubiquitination of Aurora kinase A and (c) stabilization of the substrates Aurora kinase A and PLK1. Our study therefore uncovers MAK as a new tissue-specific negative regulator of CDH1. Regarding the phosphorylation of CDH1, we showed that MAK was able to phosphorylate CDK sites, and this was not due to contaminating CDKs in the extracts. We, however, cannot rule out the presence of other MAKassociated kinase (for example, CCRK) may phosphorylate CDH1 at additional sites.
In mitosis, CDK is the major negative regulator of CDH1. Studies in yeast show that meiosis, however, is driven by cooperation between Ime2 and CDK; they phosphorylate common substrates on similar, but also distinct residues (Honigberg, 2004; Holt et al., 2007) , which are acted upon by different phosphatases, allowing multiple layers of regulatory mechanisms (Holt et al., 2007) . The fact that CDH1(9A) with all CDK phosphorylation sites mutated still maintains a low level of phosphorylation by MAK suggests that MAK has a phosphorylation specificity distinct from CDK. Given the enriched MAK expression in testis germ cells and the molecular conservation between MAK and Ime2, we speculate that MAK may be normally involved in mammalian meiosis/spermatogenesis in cooperation with CDK. However, when it is aberrantly overexpressed in prostate epithelial cells, MAK has the capacity to perturb mitosis via CDH1.
Knockdown or inhibition of CDH1 is associated with centrosome amplification and chromosome missegregation, and is implicated in genomic instability and tumorigenesis (Ross and Cohen-Fix, 2003; Wasch and Engelbert, 2005; Engelbert et al., 2008; Garcia-Higuera et al., 2008) . Cells dividing with extra centrosomes frequently end up with uneven segregation of chromosomes caused by errors on kinetochore-microtubule attachment and the subsequent lagging chromosomes (Ganem et al., 2009) . As predicted, we found that overexpression of MAK in LNCaP cell displayed stabilization of CDH1 substrates Aurora kinase A and PLK1, and defective mitosis including centrosome amplification and lagging chromosomes. As overexpression of Aurora A is known to induce centrosome amplification (Zhou et al., 1998) , the extra centrosomes observed in MAK-overexpressing LNCaP cell is likely due to cellular accumulation of Aurora A. Although the LNCaP cell line is derived from a lymph node metastasis, it is generally considered to be at relatively early stage of prostate cancer because of its androgen-dependent properties. LNCaP cells thus have been valuable for the study of prostate cancer progression. Although the genome of LNCaP cell is hypotetraploid, the karyotype and chromosome numbers remain stable after repeated subculturing (Gibas et al., 1984; Pan et al., 1999) . Additionally, the centrosome numbers is more stable in LNCaP cell compared with that in p53-deficient PC3 and DU145 cells (Ouyang et al., 2001) . For these reasons, LNCaP cell was a suitable cell line to study the effect of MAK overexpression on mitosis. It will be of interest to study whether long-term MAK overexpression in LNCaP cells would ultimately induce CIN and a more aggressive tumorigenic phenotype.
Finally, we speculate that there are two mechanisms whereby MAK inactivates CDH1: the first is kinasedependent inactivation, modeled after CDK, where phosphorylation dissociates CDH1 from APC/C; the second is through physical binding of CDH1 with MAK. The latter is reflected by the ability of MAK (KR) to inhibit CDH1-dependent ubiquitination, albeit to much less extent. There are precedents for the latter mechanism with examples provided by other CDH1 inhibitors such as Emi1, Mad2B and Id1, acting by preventing either substrate binding or substrate releasing (Pfleger et al., 2001; Reimann et al., 2001; Wang et al., 2008) . MAK physically interacts with CDH1 through the WD40 repeats, a domain known to be involved in substrate binding. It is therefore plausible that the physical interaction between MAK and CDH1 has inhibitory effect on CDH1 through substrate competition. These two mechanisms are not mutually exclusive and deserve further investigations.
In summary, this study shows that MAK is overexpressed in prostate tumors, and describes its previously unidentified role in negatively regulating APC/ C CDH1 , leading to mitotic defects (Figure 8 ). We proposed that at early cancer stage, MAK serves as a co-activator of AR; at late stage, it may contribute to CIN via deregulating APC/C CDH1 . Given its male tissue specificity, MAK presents itself as a potential target.
Materials and methods
MAK antibody
The MAK rabbit polyclonal antibody was generated against fragment aa 290-400 in non-catalytic domain to avoid cross reactivity toward other family members. The GST-MAK (290-400) protein was purified from bacteria and submitted to Covance Inc. (Princeton, NJ, USA) for animal immunization and serum collection. The crude sera were subjected to GSTimmobilized column (Pierce Biotech, Rockford, IL, USA) and MAK (290-400)-conjugated affinity column to purify specific-MAK antibodies.
Plasmids
The N-terminal Flag-tagged wt and kinase inactive MAK expression plasmids were obtained from the previous study (Ma et al., 2006) . Site-directed mutagenesis of MAK on the TDY motif was made by Quik-Change (Stratagene, La Jolla, CA, USA). The Wt and mutated MAK genes were cloned into pEF6/V5-His TOPO TA expression vector (Invitrogen, Carlsbad, CA, USA) to make C-terminal V5H-tagged expression plasmids. CDH1 and Aurora A were obtained from the IMAGE human cDNA library, CCRK DNA was a gift kindly provided by Dr Robert P Fisher (Wohlbold et al., 2006) . These genes were cloned into pcDNA3.1 expression vector with Nterminal HA or Flag tagged.
Cell culture and synchronization Primary PrEC cells were purchased from Clonetics (Walkersville, MD, USA) and cultured following the vendor's directions. Cell lines LNCaP (LNCaP-FGC), CWR22Rv1 (22Rv1), DU145, PC3, HEK293 and HEK293T (293T) were purchased from ATCC, and were cultured under conditions as recommended. Synchronization of the HEK293 cells at the G1/S boundary was induced by double-thymidine treatment: the culture was treated with 2 mM thymidine for 16 h, washed with phosphatebuffered saline and released in complete medium for 9 h, followed by second treatment of 2 mM thymidine for 15 h. 
